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In this study, a new compound, 4-(N)-docosahexaenoyl 2′, 2′-difluorodeoxycytidine (DHA-dFdC), was synthesized
and characterized. Its antitumor activity was evaluated in cell culture and in mouse models of pancreatic cancer.
DHA-dFdC is a poorly soluble, pale yellow waxy solid, with a molecular mass of 573.3 Da and a melting point of
about 96°C. The activation energy for the degradation of DHA-dFdC in an aqueous Tween 80–based solution is
12.86 kcal/mol, whereas its stability is significantly higher in the presence of vitamin E. NCI-60 DTP Human Tumor
Cell Line Screening revealed that DHA-dFdC has potent and broad-spectrum antitumor activity, especially in
leukemia, renal, and central nervous system cancer cell lines. In human and murine pancreatic cancer cell lines,
the IC50 value of DHA-dFdC was up to 10
5-fold lower than that of dFdC. The elimination of DHA-dFdC in mouse
plasma appeared to follow a biexponential model, with a terminal phase t1/2 of about 58 minutes. DHA-dFdC
significantly extended the survival of genetically engineered mice that spontaneously develop pancreatic ductal
adenocarcinoma. In nude mice with subcutaneously implanted human Panc-1 pancreatic tumors, the antitumor
activity of DHA-dFdC was significantly stronger than the molar equivalent of dFdC alone, DHA alone, or the
physical mixture of them (1:1, molar ratio). DHA-dFdC also significantly inhibited the growth of Panc-1 tumors
orthotopically implanted in the pancreas of nude mice, whereas the molar equivalent dose of dFdC alone did not
show any significant activity. DHA-dFdC is a promising compound for the potential treatment of cancers in organs
such as the pancreas.
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Docosahexaenoic acid (DHA, 22:6, n-3) is a polyunsaturated fatty
acid (PUFA) that has been extensively investigated for its potential
antitumor activity, either as a single agent or in combination with
other cancer chemotherapeutic agents [1–5]. Omega-3 PUFAs are
known to induce apoptosis in various cancer cells [6,7], inhibit cancer
cell invasiveness [8], and inhibit metastasis and angiogenesis in tumor
tissues [9–11]. The exact mechanism underlying the antitumor
activity of omega-3 PUFAs remains unknown, but it is thought to be
in part related to its potent antioxidant activity [6]. To better take
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conjugated with some commonly used cancer chemotherapeutic
agents, such as paclitaxel, doxorubicin, and camptothecin [12–14].
For example, Bradley et al. showed that conjugation of DHA to
paclitaxel significantly modified the pharmacokinetics and biodis-
tribution of paclitaxel, prompting the testing of the DHA-paclitaxel
conjugate (i.e., Taxoprexin) in clinical trials [14–16], although the
DHA-paclitaxel conjugate was not more cytotoxic than paclitaxel
alone against many tumor cells in culture [14,17,18].
Gemcitabine HCl (2′, 2′-difluorodeoxycytidine HCl, dFdC) is a
fluorinated deoxycytidine analogue. It is one of the standard treatments
of locally advanced and metastatic pancreatic cancer [19,20] and is also
used in combination therapy of other solid tumors including breast,
bladder, lung, and ovarian cancers [19,21,22]. Extensive deamination at
the 4-amino site, which takes place both intracellularly and extracellularly
by the action of cytidine deaminase, is responsible for the loss of about
90% of dFdC after intravenous administration, and the deaminated
metabolite difluorodeoxyuridine is almost inactive [19,23–26]. More
than 99%of administered dFdC is excreted in the urine, with unchanged
dFdC comprising only 5% [19,27]. Over the years, there have been
reports showing that chemical modifications of this fluorinated
deoxycytidine analogue may potentially improve its efficacy and/or
safety profiles. For example, it was shown that conjugation of a fatty acid,
such as stearic acid, to dFdC at the 4-NH2 group decreases the sensitivity
of the latter to deaminase; modifies its pharmacokinetics; and, in some
cases, improves its in vivo antitumor activity [24,28–41].
In the present study, we report the synthesis, characterization, and
in vitro and in vivo evaluations of 4-(N)-docosahexaenoyl 2′,
2′-difluorodeoxycytidine (DHA-dFdC) conjugate. DHA-dFdC
showed potent and broad spectrum antitumor activity in various
human cancer cell lines in culture. DHA-dFdC also showed an
unexpectedly longer residence time in mouse pancreas compared with
dFdC. Because pancreatic cancer is one of the most aggressive, and in
most cases fatal, types of cancer, with a mortality rate almost equal to
incidence rate [42,43], the antitumor activity of the DHA-dFdC was
primarily evaluated in mouse models of pancreatic cancer.
Materials and Methods
Materials
Gemcitabine HCl (dFdC) was from Biotang, Inc. (Lexington, MA).
Cis-4,7,10,13,16,19-docosahexaenoic acid (DHA), 1-(3-dimethylamino-
propyl)-3-ethylcarbodiimide HCI and trifluoroacetic acid (TFA) were
from Acros Organics (Morris Plains, NJ). Di-tert-butyl-dicarbonate,
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT),
vitamin E, HPLC-grade methanol, sodium dodecyl sulfate (SDS), Triton
X-100, and Tween 80 were from Sigma-Aldrich (St. Louis, MO).
Hydroxy-7-azabenzotriazole was from CreoSalus, Inc. (Louisville, KY).
Isopropylmyristate (IPM)was fromTCIAmerica (Montgomeryville, PA).
Anhydrous sodium sulfate, ammonium chloride, mono- and di-basic
sodium phosphates, ethyl acetate, HPLC-grade acetonitrile, dichlorometh-
ane (DCM), acetone, hexane, and octanol were from Thermo Fisher
(Waltham,MA). BDMatrigel BasementMembraneMatrix was fromBD
Biosciences (San Jose, CA). D-Luciferin K+ salt bioluminescent substrate
was from Perkin Elmer (Waltham, MA). Guava Nexin reagent for flow
cytometry was from EMD Millipore (Billerica, MA). Lactate dehydroge-
nase (LDH) cytotoxicity detection kit was from Takara-Clontech
Laboratories, Inc. (Mountain View, CA). Dulbecco’s modified Eagle
medium (DMEM), Roswell Park Memorial Institute (RPMI 1640)medium, fetal bovine serum (FBS), penicillin, streptomycin, horse serum,
and Dulbecco’s phosphate buffer saline were all from Invitrogen-Life
Technologies (Carlsbad, CA). All other chemicals, reagents, and solvents
were of analytical grade and used as received without further purification.
Cell Lines
Panc-02 (mouse pancreatic cancer cell line), BxPC-3 (humanpancreatic
cancer cell line), MIA PaCa-2 (human pancreatic cancer cell line), and
TC-1 (mouse lung cancer cell line) were from the American Type Culture
Collection (ATCC, Manassas, VA). Panc-1-luc human pancreatic cancer
cell line was generously provided byDr. Dawn E. Quelle at the University
of Iowa [44]. TC-1 andPanc-02 cells were grown inRPMI1640medium.
BxPC-3, MIA PaCa-2, and Panc-1-luc cells were grown in DMEM. All
media were supplemented with 10% FBS, 100 U/ml of penicillin, and
100 g/ml of streptomycin, and the DMEM for MIA PaCa-2 cells was
supplemented additionally with 2.5% horse serum.
Synthesis of DHA-dFdC
DHA-dFdC was synthesized following a previously reported
conjugation scheme with slight modifications [24,25,29] (Scheme 1).
Briefly, dFdC (1) (200 mg, 0.67 mmol) in 13.3 ml of 1 N
potassium hydroxide was cooled to 4°C. To this solution,
di-tert-butyl dicarbonate (Boc2O, 1.483 g, 6.8 mmol) in 13.3 ml
of anhydrous dioxane was added over 10 minutes under argon
atmosphere as previously reported [45]. The reaction mixture was
stirred at room temperature (~22°C) for 1 hour and extracted with
ethyl acetate (EtOAc). The organic layer was washed with brine, dried
over anhydrous sodium sulfate (Na2SO4), and filtered. Solvent was
removed under reduced pressure. The residue was added to Boc2O
(1.483 g, 6.8 mmol) in 13.3 ml of anhydrous dioxane and 13.3 ml
of 1 M KOH at room temperature. The reaction was monitored by
thin-layer chromatography. After 1 hour, the reaction mixture was
extracted to EtOAc. The organic layer was washed with brine, dried
over anhydrous Na2SO4, and filtered. Solvent was then removed, and
the crude product was purified by column chromatography (DCM to
acetone, 1:1, v/v). The desired product fractions were pooled and
dried to yield 219 mg (71%) of 3′,5′-O-bis(tert-butoxycarbonyl)
dFdC (2). 1H nuclear magnetic resonance (NMR) (500 MHz,
acetone-d6) δ 7.60 (1 H, d, J = 7.6 Hz, 6-CH), 6.34 (1 H, brs,
1′-CH), 5.97 (1 H, d, J = 7.6 Hz, 5-CH), 5.29 (1 H, brs, 3′-CH),
4.53-4.39 (3 H, m, 4′-CH, 5′A-CH, 5′B-CH), 2.82 (2 H, s, NH2)
1.50, 1.47 (18 H, two s, (CH3)3C). A solution that contains
3′,5′-O-bis(tert-butoxycarbonyl) dFdC (150 mg, 324 μmol), DHA
(123 mg, 373.9 μmol), and hydroxy-7-azabenzotriazole (75 mg,
551.1 μmol) in anhydrous DCM was precooled to 4°C, and
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide HCI (93.75 mg,
604.1 μmol) was added. The mixture was degassed by vacuum
sonication and then stirred at room temperature under argon for
about 40 hours. Water (5 ml) was added to the reaction mixture and
extracted three times with amixture of EtOAc and hexane (2:1, v/v). The
combined organic phase was washed with saturated ammonium chloride
(NH4Cl) and brine and then dried over anhydrousNa2SO4. The solvent
was evaporated, and the residuewas purified by column chromatography
(EtOAc to hexane, 3:7, v/v). The conjugated amide was isolated and
quantified (~165 mg). 1H NMR was as follows: (300 MHz,
acetone-d6) δ 9.18 (1 H, s, NHCO), 7.83 (1 H, d, J =7.8 Hz,
6-CH), 7.49 (1 H, d, J = 7.8 Hz, 5-CH), 6.47-6.42 (1 H, m, 1′-CH),
5.42-5.30 (12 H, m, CH2), 5.30-5.05 (1 H, m, 3′-CH), 4.50-4.34
(3 H, m, 4′-CH and 5′-CH), 2.90-2.79 (10 H, m, CH2), 2.60-2.40
DHA-dFdC(3)
Molecular mass: 
573.3014 g/mol
Formula: C31H41F2N3O5
ARA-dFdC
Molecular mass: 
549.3014 g/mol
Formula: C29H41F2N3O5
DHA
ARA
(1) (2)
Scheme 1. Synthesis of DHA-dFdC and ARA-dFdC. RT, room temperature; Ar, argon.
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(CH3)3C), 0.97 (3 H, t, J = 7.4 Hz, terminal CH3). To a stirred
solution of the conjugated amide (37 mg, 47.8 nmol) in 3 ml of DCM,
about 0.2 ml of TFA was added. This solution was stirred at room
temperature for 4 hours, and excess TFA was removed under reduced
pressure. The concentrated sample was codistilled with DCM for three
times. The crude sample was chromatographed on silica gel (DCM to
ethanol, 94:6, v/v) [25,28]. The desired fractions were pooled, and the
solvent was evaporated to yield 4-(N)-DHA-dFdC (3) (DHA-dFdC,
~80 mg, ~36% of original combined weights of dFdC and DHA),
which appeared as a pale yellow dry waxy solid. 1H NMR (300 MHz,
THF-d4) was as follows: δ 10.13 (1H, s, NHCO), 8.17 (1H, d, J =
7.5 Hz, 6-CH), 7.37 (1H, d, J = 7.5 Hz, 5-CH), 6.25 (1H, t, J =
7.4 Hz, 1′-CH), 5.51-5.27 (12H, m, CH), 4.40-4.20 (1H, m,
3′-CH), 3.95–3.70 (3H, m, 4′-CH and 5′-CH), 2.95-2.82 (10H, m,
CH2), 2.50-2.41 (4H, m, CH2), 2.08 (2H, p, J = 7.2 Hz, CH2), 0.96
(3H, t, J = 7.7 Hz, terminal CH3) (see Figure S1A in the Supplement
for 1H NMR spectrum). ESI-HRMS [M + Na] + m/z calculated
for C31H41F2N3NaO5 is: 596.29065, found: 596.29068. The
purity of the synthesized compound was confirmed by LC/mass
spectrometry (MS) following gradient elution (Figure S1, B and C,
Supplement).
The 4-(N)-arachidonyl dFdC (ARA-dFdC) was synthesized similar-
ly, except that the DHA was replaced with arachidonic acid (ARA), an
omega-6 PUFA (Scheme 1). The structure of the resultant ARA-dFdC
was confirmed using 1H NMR and MS (data not shown).Determination of the Solubility and Partition Coefficient of
DHA-dFdC
The aqueous solubility of DHA-dFdC was determined following
an indirect method according to Beall et al. with minimal
modifications [46]. Briefly, excess amount of DHA-dFdC was
added to 100 μl of IPM in crimp-sealed amber glass vials under
nitrogen and was stirred vigorously at room temperature for 24 hours,
protected from light. After the stirring was stopped, the mixture was
left to stand for an additional 24 hours for equilibration. The content
of the vial was centrifuged (14,000 rpm, 10 minutes), and the
supernatant was transferred into a different tube. Aliquots of the
saturated IPM solution were used to measure the DHA-dFdC
concentration before partitioning (A1) using HPLC (after proper
dilution with methanol). The HPLC method will be discussed in
details later. Then, water was added to the IPM saturated solution in a
volume ratio of 10:1. The two phases were mixed by vortexing for
5 minutes, left to stand for 15 minutes, and then centrifuged
(14,000 rpm, 15 minutes) to collect the IPM layer. DHA-dFdC
concentration in the IPM layer (A2) was again measured using HPLC
after partitioning. The following equation was used to calculate the
partition coefficient (KIPM/water) [46]:
K IPM=water ¼ A1= A1–A2ð Þ½   Vwater=V IPM½  ð1Þ
Where Vwater is the volume of the water phase and VIPM is the
volume of IPM, and the value of Vwater/VIPM was 10.
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the following equation [46]:
Sw ¼ S IPM=K IPM=water ð2Þ
Where SIPM is the solubility of DHA-dFdC in IPM, and
DHA-dFdC was found to be stable in IPM under test conditions
for at least 48 hours.
The octanol-water partition coefficient of DHA-dFdC was
determined using a previously reported method with minor
modifications [47]. Briefly, octanol and PBS (7.4, 0.01 M) were
mutually saturated for 24 hours. DHA-dFdC was dissolved in
octanol (0.4 mg/ml, PBS-saturated), and 10 μl of the solution was
withdrawn and diluted with methanol to measure DHA-dFdC
concentration using HPLC (C1). PBS was added to octanol at a
volume ratio (VPBS/Voct) of 20:1 into a sealed vial under nitrogen, and
the mixture was agitated vigorously at room temperature using a
horizontal orbital shaker at 250 rpm (Max Q 2000, Thermo
Scientific) while protected from light. After 5 hours, the mixture
was centrifuged (14,000 rpm, 15 minutes), and the concentration of
DHA-dFdC in the octanol layer was determined using HPLC (C2).
Partition coefficient (Koct/water) was calculated using the following
equation:
Koct=water ¼ C1= C1–C2ð Þ½   V PBS=V oct½  ð3Þ
DHA-dFdC was found to be stable in octanol under the test
conditions for at least 18 hours (data not shown).
Chemical Stability of DHA-dFdC in an Aqueous Solution
DHA-dFdC is freely soluble in ethanol and in Tween 80. It was
solubilized into a formulation that contains Tween 80, ethanol, and
water (volume ratio, 1:0.52:8.48) to evaluate its in vivo activity. The
stability of DHA-dFdC in this formulation was evaluated in
crimp-sealed amber glass vials under nitrogen atmosphere. Briefly,
150 μl of the DHA-dFdC aqueous solution at a concentration of
about 7 mg/ml was added to the amber glass vials under nitrogen
atmosphere, and the vials were crimp-sealed with aluminum seals over
rubber lids. At predetermined time intervals, 10 μl of the solution
was diluted with 90 μl of methanol and mixed, and the concentration
was measured using HPLC. Stability tests were carried out at room
temperature (~22°C) or 4°C in triplicates. Vitamin E was added in
the formulation to a final concentration of 0.01% or 0.04% (v/v) to
evaluate the effect of vitamin E on the chemical stability of
DHA-dFdC.
To study the effect of temperature on the chemical stability of
DHA-dFdC, the DHA-dFdC formulation in crimp-sealed vials under
nitrogen was stored at room temperature, 37°C, or 60°C, protected from
light. Sampling and analyses were carried out at predetermined time
points as described above. The first-order degradation reaction equation
was used to calculate the values of the reaction rate constant (k) at different
temperatures. Arrhenius plot was constructed by plotting the log k values
versus 1/T to calculate the activation energy (Ea, in kcal/mol) [48].
Physicochemical Characterizations of DHA-dFdC
The UV-Vis absorbance of DHA-dFdC, DHA, dFdC, and the
physical mixture of dFdC and DHA, all dissolved in methanol, was
evaluated using a BioTek Synery HTMulti-Mode Microplate Reader
(Winooski, VT) using the scanning mode. Modulated differential
scanning calorimetry (DSC) was used to evaluate the thermalproperties of DHA-dFdC. Samples (2-4 mg) were placed in sealed
pans, and the DSC analysis was carried out using DSC Q200 (TA
Instruments, New Castle, DE) at a ramp rate of 5°C/min under
nitrogen flow. X-ray diffraction (XRD) analyses of DHA-dFdC, dFdC,
DHA, and the physical mixture of dFdC and DHA (1:1, m/m) was
carried out in the x-ray facility in the Department of Chemistry at the
University of Texas at Austin using a Rigaku Spider single-crystal x-ray
diffractometer (Rigaku, Tokyo, Japan).
Evaluation of the Cytotoxicity of DHA-dFdC in Tumor Cells
in Culture
The cytotoxicity DHA-dFdC was tested using the NCI-60 DTP
Human Tumor Cell Line Screen service (http://dtp.nci.nih.gov/
branches/btb/ivclsp.html). The NCI-60 cell lines do not include any
pancreatic cancer cell lines. Therefore, DHA-dFdC was also evaluated
in mouse (Panc-02) and human (Panc-1-luc, and BxPC-3) pancreatic
cancer cell lines. TC-1 is a mouse lung cancer cell line that grows
aggressively in mice [24]. The cytotoxicity of DHA-dFdC was also
evaluated in TC-1 cells. For TC-1, Panc-02, BxPC-3, and Panc-1-luc
cells, cells (1500/well for Panc-02, BxPC-3, and Panc-1-luc, and
3000/well for TC-1) were seeded in 96-well plates and incubated at
37°C and 5% CO2 overnight. The cells were then treated with
various concentrations of DHA-dFdC, dFdC, DHA, or physical
mixture of dFdC and DHA (i.e., DHA + dFdC, 1:1 molar ratio) for
24 hours for Panc-1-luc and TC-1, 48 hours for Panc-02, and
72 hours for BxPC-3. Cell survival was determined using an MTT
assay as previously described [49]. DHA-dFdC, DHA, and DHA and
dFdC mixture were dissolved in dimethyl sulfoxide (DMSO),
whereas dFdC was dissolved in cell culture media. In a separate
experiment, Panc-02 cells were also treated for 4 hours with higher
concentrations of DHA-dFdC (i.e., 10-100 μM) or molar equivalent
concentrations of dFdC, DHA, or dFdC + DHA (1:1 m/m), and
cytotoxicity was measured using MTT assay. The cytotoxic activity of
DHA-dFdC in Panc-02 cells was also evaluated using an LDH assay
kit. Briefly, Panc-02 cells (1500 cells/well) were seeded in 96-well plates
and incubated at 37°C and 5% CO2 for 24 h, followed by treatment
with DHA-dFdC or dFdC as mentioned above for 48 hours. LDH
activity in the cell culture medium was determined following the
manufacturer’s instruction. Finally, the cytotoxicity of the ARA-dFdC
was also evaluated in MIA PaCa-2 and BxPC-3 cells using MTT assay
(1000 cells/well, 72 hours of treatment) as mentioned above. The
values of IC50 were calculated using either GraphPad Prism (GraphPad
software, Inc., La Jolla, CA) or Microsoft Excel.
Apoptosis analysis was carried out as previously reported [50].
Briefly, 100,000 Panc-02 cells were incubated in 24-well plates for
24 hours at 37°C and 5% CO2 and then coincubated with various
concentrations of DHA-dFdC for 48 hours. Cells were then
harvested and stained with 0.1 ml of Guava Nexin reagent (Millipore
Corporation, Billerica, MA) for 20 minutes at room temperature,
protected from light. The stained cells were analyzed using a Millipore
Guava EasyCyte 8HT Flow Cytometry System. Control cells were
left untreated.
Cellular Uptake of dFdC
The uptake of DHA-dFdC by Panc-02 cells was evaluated. Briefly,
250,000 cells were seeded in 12-well plates and incubated overnight,
followed by the addition of DHA-dFdC (or dFdC as a control) to a
final concentration of 10 μM. Four hours later, the medium was
removed, and cells were lysed using 500 μl of 1:1 mixture of 2% SDS
Figure 1. Chemical stability of DHA-dFdC. (A) The concentration-time curves of DHA-dFdC at room temperature (~22°C) in a solution (i.e.,
Tween 80/ethanol/water) that contained 0%, 0.01%, or 0.04% (v/v) of vitamin E. As a control, the stability at 4°C is also shown. (B)
Arrhenius plot showing the effect of temperature on the rate constant of the degradation of DHA-dFdC in a Tween 80/ethanol/normal
saline solution. Data shown are mean from at least three repeats, and standard deviations were not shown for clarity.
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was centrifuged (14,000 rpm, 10 minutes) to collect supernatant,
which was used for protein assay using Pierce BCA protein assay kit
(Life Technologies, Carlsbad, CA). For cells that were incubated with
dFdC, before the centrifugation of the cell lysate, tetrahydrouridine
(4 μl of 10 mg/ml in water) was added into the cell lysate to inhibit
deamination, and deoxyuridine (20 μl of 20 μg/ml in water) was
added as an internal standard. DHA-dFdC was extracted from the cell
lysate using ethyl acetate, which was evaporated under nitrogen, and
the residue was redissolved in 100 μl of methanol and analyzed by
HPLC. To extract dFdC, the cell lysate was mixed with acetonitrile
for protein precipitation, followed by centrifugation and collection of
the supernatant, which was evaporated under air stream at 45°C. The
residue was redissolved in 200 μl of water and analyzed using HPLC.
Standard curves were constructed using various concentrations of
DHA-dFdC or dFdC in cell lysates.
Pharmacokinetics and Biodistribution of DHA-dFdC
Animal protocols were approved by the Institutional Animal Care
and Use Committee at the University of Texas at Austin. Healthy
female C57BL/6 mice (6-8 weeks, Charles River Laboratories,
Wilmington, MA) were injected intravenously (IV) with DHA-dFdC
in Tween 80/ethanol/water (with 5% mannitol) solution at the dose
of 75 mg/kg. At various time points (5, 15, 30, 60, 120, and
180 minutes), 3 mice were euthanized to collect blood. DHA-dFdC
was extracted from plasma using ethyl acetate and analyzed using
HPLC. Data were analyzed using the Pharsight WinNonlin software
(Sunnyvale, CA). Pancreatic DHA-dFdC levels were evaluated in
healthy female BALB/c mice (17-20 weeks old, Charles River)
following IV injection of the mice with DHA-dFdC in a Tween 80/
ethanol/5% mannitol aqueous solution (75 mg/kg). At various time
points (i.e., 5, 30, 60, 90, 180, and 300), mice were euthanized (n =
3-4 per time point).The pancreas was collected and homogenized,
and DHA-dFdC was extracted using ethyl acetate and analyzed using
HPLC. As a control, the content of dFdC in mouse pancreas was also
measured at various time points after mice were IV injected with
dFdC (75 mg/kg in 5% mannitol solution). Before extraction of dFdC,
tetrahydrouridine was added as a deoxycytidine deaminase inhibitor,deoxyuridine was added as an internal standard, and dFdCwas quantified
using HPLC, as previously reported with modification [51]. The area
under the DHA-dFdC pancreatic level curve was calculated and
compared with that of dFdC using the PKSolver following a
noncompartmental model and extravascular administration [52].
HPLC
HPLCanalysis ofDHA-dFdCwas performedusing anAgilent Infinity
1260 (Agilent Corp., Santa Clara, CA) with a RP-C18 column (Zorbax
Eclipse, 5 μm, 4.5 mm × 150 mm, Santa Clara, CA).The mobile phase
was methanol and water (90:10, v/v). The flow rate was 1.0 ml/min, and
the detection wavelength and injection volume were 248 nm and 5 μl,
respectively.When cell lysate, mouse plasma, or tissue samples were used,
the mobile phase was methanol and 1% (v/v) acetic acid in water (85:15,
v/v) with a flow rate of 1.2 ml/min and injection volume of 20 μl. When
DHA-dFdC levels were assayed in pancreatic tissues, the detection
wavelength was 300 nm. The concentration of dFdC was determined
using a previously reported method with modifications [51]. Briefly, an
Agilent 1260 Infinity HPLC Station equipped with a RP-C18 column
(Zorbax Eclipse, 5 μm, 3 mm × 150 mm) at a controlled temperature of
20°C, an Agilent quaternary pump, and an Agilent Diode array UV
detector was used. The mobile phase was composed of solution A
(phosphate buffer, pH adjusted to 3.0 using phosphoric acid) and
solution B (acetonitrile). The column was equilibrated using solution A
for at least 30 minutes at a flow rate of 0.6 ml/min followed by another
30 minutes at 1.2 ml/min. The gradient elution consisted of 100%
solution A for 6 minutes followed by a gradual change to 97% solution A
and 3% solution B over 1 minute. This composition was maintained for
2 minutes, and the composition was returned back to 100% solution A
over 1 minute. Between runs, the column was rinsed with methanol:-
water (90:10, v/v) and methanol:water (50:50, v/v), each for about
15 minutes, and then equilibrated with solution A. The flow rate was
1.2 ml/min. The detection wavelength was 276 nm.
Evaluation of the Antitumor Activity of DHA-dFdC in Animal
Models
Transgenic mice with spontaneously developed pancreatic tumors. Fe-
male Kras Ink4a+/− mice bred in the Animal Research Center at the
Figure 2. (A) XRD patterns of DHA-dFdC, dFdC, DHA, and the mixture of dFdC and DHA (i.e., DHA + dFdC, 1:1, m/m). (B) UV/Vis spectra
of DHA-dFdC and DHA at various concentrations, and a comparison of the UV/Vis spectra of DHA-dFdC, dFdC, DHA, and DHA + dFdC
physical mixture. (C) DSC analyses of DHA-dFdC precipitated from ethanol solution (solid line) or ether (dashed line).
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spontaneously develop pancreatic tumors that resemble human
pancreatic tumors [53]. To accelerate pancreatic tumor development,
mice were transferred to a special diet (D1249, 60% kcal fat; Research
Diets, Inc., New Brunswick, NJ) at the age of 16 weeks [53]. Starting at
the age of 20 weeks, mice were grouped and treated with DHA-dFdC
[n = 5, 50 mg/kg, intraperitoneal (IP) injection, up to twice a week for
total of 29 doses] or left untreated (n = 6), and their health and survival
were monitored. In another experiment, female Kras Ink4a+/− mice that
were placed on the special high fat diet at 10 to 12 weeks of age were
randomized into 2 groups (n = 6) at the age of 19 to 20 weeks and were
either treated with DHA-dFdC (65 mg/kg, IP, twice a week) or left
untreated until week 30. Mice were then euthanized, and their pancreas
were collected, fixed in formalin, and embedded in paraffin blocks for
histological evaluation.
Mice with subcutaneous Panc-1-luc tumors. Male athymic nude
mice (6-8 weeks, Charles River) were subcutaneously (SC) injected
with Panc-1-luc cells (5 × 106 cells in a DMEM and Matrigel
mixture, 1:1 v/v). When tumors reached 5 to 7 mm, mice were
randomized into 5 groups (n = 5-6) and injected with DHA-dFdC
(IP, 50 mg/kg, or ~0.087 mol/kg, n = 6), dFdC (26.1 mg/kg, or~0.087 mol/kg, n = 6), DHA (28.7 mg/kg, or ~0.087 mol/kg,
n = 5), or the physical mixture of dFdC (26.1 mg/kg) and DHA
(28.7 mg/kg) (n = 6). DHA-dFdC, DHA alone, and the mixture of
DHA and dFdC were dissolved in Tween 80/ethanol/water at a ratio
of 1:0.52:8.48 with 5% w/v mannitol, whereas dFdC alone was
dissolved in 5% w/v of mannitol solution. As a vehicle control, mice
were also injected with the Tween 80/ethanol-based solution alone
(n = 6). Treatments were repeated twice a week for up to six times,
and tumor growth was monitored using a digital caliper. Tumor
volumes (V) were calculated based on the longest diameter (L1) and
the shortest diameter (L2) of each tumor using the equation of V = ½ ×
L1 × L2 × L2 [54].
Mice with orthotopic Panc-1-luc tumors. Panc-1-luc cell suspen-
sion was prepared at a concentration of about 2 × 107 per ml in a 1:1
(v/v) mixture of DMEM and Matrigel. Tumor cells were then
injected into the pancreas of male athymic nude mice (6-8 weeks,
Charles River) following a surgical procedure [55,56]. Briefly, after
mice were anesthetized using isoflurane, the skin and peritoneum
were cut open about 1 cm in length using sterile surgical scalpels. The
pancreas was pulled out, and about 50 μl of the cell suspension was
injected slowly until a small bleb was formed. After the needle was
Table 1. Cytotoxic activity of DHA-dFdC against NCI-60 DTP Human Tumor Cell Lines
Cell line GI50 (μM) TGI (μM) LC50 (μM)
Leukemia CCRF-CEM 0.0507 17.9 N100
HL-60 (TB) 0.029 14.8 N100
K-562 0.0674 46.9 N100
MOLT-4 0.0692 13.3 93.1
RPMI-8226 0.0538 26.9 N100
SR 0.0141 28.8 N100
Non-small cell lung cancer A549/ATCC 0.0326 15.4 43.8
EKVX 0.852 20.4 52.9
HOP-62 0.0186 4.47 35.2
HOP-92 0.771 34.5 N100
NCI-H226 0.0672 2.75 39.2
NCI-H23 0.0157 12.7 56.6
NCI-H322M 1.18 19 46
NCI-H460 0.0153 11.8 43.3
NCI-H522 0.028 14.2 54.1
Colon Cancer COLO 205 0.143 14.1 50.7
HCC-2998 10.6 26.7 67.5
HCT-116 0.0311 15.3 44.4
HCT-15 1.86 25.3 87.5
HT29 0.0683 17.6 45.1
KM12 1.05 20.2 51.9
SW-620 0.0759 23.2 84.4
CNS Cancer SF-268 0.0542 12.9 42.3
SF-295 0.0791 10.9 37.5
SF-539 0.0287 0.538 30.6
SNB-19 0.0223 12.4 61.9
SNB-75 0.401 25.1 N100
U251 0.0305 15.2 43.9
Melanoma LOX IMVI 0.0414 1.07 77.9
MALME-3 M 10.1 22.8 51.6
M14 0.0243 0.21 34.8
MDA-MB-435 0.311 18.1 43.3
SK-MEL-2 13.2 29.8 67.6
SK-MEL-28 10.1 23.3 53.8
SK-MEL-5 0.29 17.1 42.1
UACC-257 0.518 22.9 56.1
UACC-62 0.0494 12.5 43
Ovarian Cancer IGROV1 3.45 22.5 55.3
OVCAR-3 11.1 23.5 49.6
OVCAR-4 14.5 28.8 57.2
OVCAR-5 0.0821 22.5 63.8
OVCAR-8 0.0345 11.4 43.2
NCI-ADR-RES 0.0338 14.8 46.9
SK-OV-3 0.11 14.2 N100
Renal Cancer 786-0 b0.01 14.2 N100
A498 0.0855 16.1 51.9
ACHN b0.01 10.1 39.4
CAKI-1 0.0253 11.7 34.3
RXF 393 0.14 15.1 45.1
SN12C 0.197 4.49 33.8
TK-10 11.5 29.4 74.9
UO-31 0.0835 12 37.9
Prostate Cancer PC-3 10.7 27 67.8
DU-145 0.0396 12.5 35.3
Breast Cancer MCF7 b0.01 13.4 42.3
MDA-MB-231/ATCC 6.82 22.2 53.5
HS 578 T 17 45.5 N100
BT-549 0.0454 16.3 44.2
T-47D 0.0996 17.6 71.9
Values shown are in μM. GI50 is the concentration of DHA-dFdC at which tumor cell growth was
inhibited by 50%. TGI is the concentration at which tumor cell growth was completely inhibited.
LC50 is the concentration at which 50% of the tumor cells were killed.
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pancreas was returned back, the peritoneum was sutured with
Monocryl bioresorbable sutures (Ethicon, Somerville, NJ), and the
skin was then closed using surgical clips. Mice were SC injected with
buprenorphine (0.1 mg/kg) as a pain killer and were left to heal for 1
week. Tumor progress was monitored using an IVIS Spectrumimaging system (Caliper, Hopkinton, MA). For IVIS imaging, each
mouse was IP injected with a luciferin solution (15 mg/ml) at a dose
of 0.15 mg/g body weight in sterile Dulbecco’s phosphate buffer
saline, anesthetized with isoflurane, and imaged 10 minutes after
luciferin injection. Four weeks after tumor implantation, mice with
tumors were randomized into 3 groups (n = 5-7) and IP injected with
DHA-dFdC (50 mg/kg, ~0.087 mol/kg) or dFdC (26.1 mg/ml,
~0.087 mol/kg), or left untreated. Again, DHA-dFdC was dissolved
in a Tween 80/ethanol/water solution with 5% (w/v) of mannitol,
and dFdC was dissolved in sterile mannitol solution (5%, w/v).
Treatments were repeated twice a week for a total of seven times.
Thirty days after the first treatment, mice were sacrificed, and tumors
were dissected from the pancreas, weighed, fixed in formalin,
dehydrated in 70% ethanol, and embedded in paraffin wax.
In both studies mentioned above, the doses were based on the
average weight of mice in the same group on the day of injection and
were adjusted only if the weight of an individual mouse was above or
below 10% of the average weight.
Mice with subcutaneous TC-1 tumors. The in vivo antitumor
activity of DHA-dFdC was also evaluated in female C57BL/6 mice (6-8
weeks, Charles River) with SC implanted TC-1 mouse lung cancer cells.
Briefly, 5 × 105 cells in RPMIwere SC injected in the right flank of female
C57BL/6 mice. Eight days later, mice were randomized into 3 groups
(n = 5-6) and IP injected with DHA-dFdC (50 mg/kg, ~ 0.087 mol/kg)
or dFdC solution (26.1 mg/kg, ~0.087 mol/kg), or left untreated as a
control. Treatments were repeated every 3 to 4 days for a total of 4 times.
Tumor growth was monitored using a digital caliper.
Immunohistochemistry
Tumor tissues were sectioned and stained in the Histology and Tissue
Analysis Core at Dell Pediatric Research Institute at the University of
Texas at Austin or in the Department ofMolecular Carcinogenesis at the
University of Texas M.D. Anderson Cancer Center at Science Park
(Smithville, TX) with hematoxylin and eosin (H&E), or antibodies
against cleaved lamin-A (apoptosis marker) or Ki-67 (proliferation
marker). Slides were then scanned, and images were taken using the
ScanScope XT (Aperio Technologies, Vista, CA). In the animal study
usingKras Ink4A+/−mice, pancreas tissues were examined to evaluate the
progression of pancreatic ductal adenocarcinoma (PDAC).
Statistical Analysis
Statistical analyses were completed by performing analysis of variance
followed by Fisher’s protected least significant difference procedure.
Survival curve comparisons were constructed using Kaplan-Meier
survival analysis (GraphPad Prism). The survival curves were compared
using the log-rank test (Mantel-Cox test). A P value of ≤ .05 (two-tailed)
was considered statistically significant.
Results
Solubility, Partition Coefficient, and Stability of DHA-dFdC
Beall et al. reported a method to measure the aqueous solubility of
drug molecules that are unstable in water [46], which was adopted in
the present study. To validate the method, the aqueous solubility of
4-(N)-stearoyl dFdC, another lipophilic dFdC conjugate [24], which
is stable in water, was measured directly (i.e., direct method) or using
the indirect method reported by Beall et al. [46]. The solubility of
4-(N)-stearoyl dFdC in water was found to be 1.38 ± 1.60 μg/ml when
it was measured using the direct method and 1.39 ± 0.10 μg/ml using
the indirect method. Therefore, the indirect method was used to
Figure 3. (A-D) Cytotoxicity of DHA-dFdC and molar equivalent concentrations of other treatments against BxPC-3 cells after 72 hours (A),
Panc-1-luc cells after 24 hours (B), Panc-02 cells after 48 hours (C), and Panc-02 cells after 4 hours (D) of incubation, all measured using
an MTT assay. (E) Cytotoxicity of DHA-dFdC and dFdC against Panc-02 cells after 48 hours of incubation, measured using an LDH assay.
(F) Proapoptotic activity of DHA-dFdC against Panc-02 cells after staining with Annexin V–PE and 7-AAD. Quarters are: top left, cellular
debris, bottom left: live cells, top right: late apoptotic cells, and bottom right: early apoptotic cells. (G) Percent of viable and apoptotic
cells after Panc-02 cells were treated with various concentrations of DHA-dFdC. (H) A comparison of the IC50 values of dFdC and
ARA-dFdC in MIA PaCa-2 and BxPC-3 cells (n.s., not significant). Data shown are mean ± SD (n N 3).
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Figure 4. Uptake of DHA-dFdC by Panc-02 cells in culture. Cells
(250,000/well) were coincubated with DHA-dFdC (10 μM in DMSO)
or dFdC (10 μM in cell culture medium) for 4 hours. Data are
mean ± SD (n = 3-4).
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25.15 ± 11.20 μg/ml.
The partition coefficient of DHA-dFdC in octanol versus PBS
(pH 7.4) was also measured using an indirect method by determining
its concentration in octanol before and after partitioning. The logP
value of DHA-dFdC was found to be 2.24 ± 0.25.
DHA-dFdC solubilized in a Tween 80/ethanol/water formulation
was found to degrade considerably at room temperature (~22°C)
(Figure 1A). The degradation was significantly slower at 4°C and was
also significantly slower in the presence of vitamin E. Vitamin E at
0.01% (w/v) was more effective than at 0.04% (w/v). It was reported
previously that a higher concentration of vitamin E may not
necessarily have a higher antioxidative activity [57]. The effect of
temperature on the chemical stability of DHA-dFdC is shown in
Figure 1B. The activation energy of the chemical reaction was
calculated to be 12.86 kcal/mol.
XRD, UV/Vis, and DSC Profiles of DHA-dFdC
X-ray diffraction pattern showed that the major crystallinity peaks
related to dFdC at the 2 theta values of 9.5, 15.4, 19.0, 21.0, 23.0, 27.5,
30.5, and 35.5 were retained in the physical mixture of dFdC and DHA
but disappeared in DHA-dFdC (Figure 2A). UV/Vis scanning revealed
that the maximum absorption peak (λmax) of DHA-dFdC in methanol
was 248 nm, and there is another absorption peak at 300 nm
(Figure 2B). The λmax values of dFdC and DHA were 276 nm and
234 nm, respectively (Figure 2B). DSC analysis of DHA-dFdC showed a
melting point of ~96°C (Figure 2C).
The Cytotoxicity of DHA-dFdC against Tumor Cells in Culture
The cytotoxicity of DHA-dFdC was evaluated in the NCI-60 DTP
human tumor cell lines, and the results are shown in Table 1. In
about two thirds of the cell lines tested, DHA-dFdC was more potent
than dFdC (Figure S2, Supplement). The NCI-60 DTP human
tumor cell lines do not include any pancreatic tumor cell line;
therefore, the cytotoxicity of DHA-dFdC was evaluated in several
human and mouse pancreatic cancer cell lines (i.e., Panc-02, Bx-PC3,
Panc-1) using an MTT assay. In all three cell lines, DHA-dFdC was
more cytotoxic than dFdC or the physical mixture of dFdC and DHA(1:1, molar ratio), and the physical mixture of DHA and dFdC was
not more cytotoxic than dFdC alone (Figure 3, A–D). LDH assay
also confirmed that DHA-dFdC was more cytotoxic than dFdC in
Panc-02 tumor cells (Figure 3E). Data in Figure 3, F and G, show
that DHA-dFdC induced tumor cell apoptosis.
To understand the effect of the omega-3 PUFA nature of the DHA
(i.e., the docosahexaenoyl group) in the DHA-dFdC on its cytotoxicity
against tumor cells, the cytotoxicity of ARA-dFdC, a conjugate of dFdC
and ARA, an omega-6 PUFA, was also evaluated in BxPC-3 and MIA
PaCa-2 cells, and data in Figure 3H showed that ARA-dFdC was not
significantly more cytotoxic than dFdC.
Uptake of DHA-dFdC by Tumor Cells in Culture
The percent of DHA-dFdC or dFdC that was taken up by Panc-02
cells after 4 hours of incubation is shown in Figure 4. The uptake of
the DHA-dFdC was about 10-fold higher than that of dFdC.
Pharmacokinetics and Pancreatic Uptake of DHA-dFdC
The plasma DHA-dFdC levels in mice at different time points after
IV injection are shown in Figure 5A. The elimination of DHA-dFdC
in mouse plasma appears to follow a biexponential model. Selected
pharmacokinetics parameters of DHA-dFdC are shown in Figure 5B.
Preliminary study revealed that the concentration of DHA-dFdC in
the pancreas of healthy mice 1 hour following IV injection of
DHA-dFdC was among the highest compared with DHA-dFdC
concentrations in the liver, kidney, spleen, lung, and heart (data not
shown). Because monotherapy with dFdC is one of the first-line
treatments for advanced pancreatic cancer, the levels of DHA-dFdC
in mouse pancreas at various time points after IV injection were also
determined and compared with those of dFdC (Figure 5C). The
AUC0-∞ values for DHA-dFdC and dFdC were found to be
2408.00 μg/g•min and 787.71 μg/g•min, respectively.
Antitumor Activity of DHA-dFdC in Mouse Models
Because the cytotoxicity of the DHA-dFdC was up to 105-fold
higher than that of dFdC in pancreatic tumor cell lines and
DHA-dFdC showed relatively higher residence in mouse pancreas
compared with dFdC, the antitumor activity of DHA-dFdC was
initially tested in Kras Ink4a+/− transgenic mice that spontaneously
develop pancreatic tumor. Data in Figure 6A showed that treatment
with DHA-dFdC significantly extended the survival of the transgenic
mice. To confirm that the Kras Ink4a+/− mice died of pancreatic
cancer, mice were euthanized after 10 doses of DHA-dFdC. As shown
in Figure 6B, when left untreated, four of six mice showed that the
pancreas was replaced with PDAC, whereas the pancreas in the other
two mice showed several foci of PDAC and extensive pancreatic
intraepithelial neoplasia (PanIN)-2 and PanIN-3. When the mice
were treated with DHA-dFdC, the pancreas of only two of six mice
was completely replaced by PDAC, and one of six mice had about half
of its pancreas replaced with PDAC (Figure 6B). The pancreases in
two mice showed variable levels of PanIN-1, -2, and -3, with only
limited PDAC foci, and the pancreas of one mouse appeared to be
normal (Figure 6B).
The antitumor activity of DHA-dFdC was then evaluated and
compared with that of the dFdC or the physical mixture of dFdC and
DHA in mice with SC injected human Panc-1-luc tumor cells. As
shown in Figure 7A, at the dosing regimen used, DHA-dFdC
significantly inhibited Panc-1-luc tumor growth as compared with the
vehicle control, but the molar equivalent doses of dFdC alone, DHA
Figure 5. Plasma and pancreatic tissue pharmacokinetics of DHA-dFdC. (A) Plasma DHA-dFdC concentration-time curve following IV
injection of DHA-dFdC into C57BL/6 mice (75 mg/kg). (B) Selected plasma pharmacokinetics parameters of DHA-dFdC. Data in A were
fitted in two-compartment model. (C) Pancreatic tissue DHA-dFdC and dFdC concentration curves following IV injection of BALB/c mice
with DHA-dFdC or dFdC alone (75 mg/kg). Data in A and C are mean ± SD (n = 3-4).
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did not significantly inhibit the tumor growth. Shown in Figure 7B
are body weights of mice that were treated with DHA-dFdC, DHA
alone, dFdC alone, or the physical mixture of DHA and dFdC.
In mice with orthotopic Panc-1-luc tumors, DHA-dFdC at the
dosing regimen tested significantly inhibited the tumor growth, but
the molar equivalent dFdC did not show significant activity (Figure 8,
A–C). Shown in Figure 8D are the body weights of mice that were
treated with DHA-dFdC or dFdC. H&E staining of the tumor tissues
revealed that tumors in mice that were left untreated have much larger
tumor volume and the tumors are poorly differentiated (Figure 9A).
In addition, areas of necrosis can be seen in the centers of the tumors
(lined in green). A similar pattern was observed in tumors in mice that
were treated with dFdC but with less necrosis (Figure 9A). On the
contrary, tumors in mice that were treated with DHA-dFdC showed
smaller tumor volume (Figure 9A). Ki-67 staining showed that there
is a significantly lower cell proliferative index (Ki-67) in tumors in
mice that were treated with DHA-dFdC when compared with mice
that were treated with dFdC (Figure 9, A and B). Anti–cleaved
lamin-A staining showed a significantly higher percent of positive
staining in tumors in mice that were treated with DHA-dFdC than in
mice that were untreated, whereas the extent of cleaved lamin A–positive staining in tumors in mice that were treated with dFdC was
not different from that in mice that were left untreated (Figure 9, A
and C).
Finally, as shown in Figure S3, DHA-dFdC was more effective
than the molar equivalent dose of dFdC in inhibiting the growth of
SC implanted TC-1 mouse lung cancer cells, demonstrating that
the in vivo antitumor activity of DHA-dFdC is not limited to
pancreatic tumors.
Discussion
In the present study, we reported the synthesis of DHA-dFdC, an
amide, by conjugating DHA and dFdC and presented 1H NMR,
MS, and LC/MS data to confirm its structure and purity.
DHA-dFdC showed potent and broad-spectrum antitumor activity
against all of the NCI-60 human tumor cell lines and several human
and mouse pancreatic tumor cell lines (Table 1, Figure 3).
Unexpectedly, biodistribution studies revealed that DHA-dFdC had
a relatively higher accumulation and slower clearance in mouse
pancreas after IV injection when compared with dFdC (Figure 5C).
Importantly, DHA-dFdC significantly extended the survival of Kras
Ink4a+/− transgenic mice that spontaneously develop pancreatic
tumors and showed a significantly stronger antitumor activity than
Figure 6. Antitumor activity of DHA-dFdC in Kras Ink4a+/−mice. (A) Survival curves of female Kras Ink4a+/−mice treated with DHA-dFdC
or left untreated. Mice were shifted from normal diet to a high-fat diet at 16 weeks of age. DHA-dFdC treatment (50 mg/kg, IP twice a
week) was started when mice were at the age of 20 weeks. (B) Representative H&E images of mouse pancreas and pancreatic tumors
from Kras Ink4a+/− transgenic mice that were treated with DHA-dFdC (IP 65 mg/kg, up to twice a week) or left untreated (n = 6). Each
tissue is represented by two magnifications: top: 1× and bottom: 20×. The scale bar in each 1× image represents 2 mm, and that in
each 20× image represents 100 μm.
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and orthotopic Panc-1 human pancreatic tumors (Figures 7-9).
There have been numerous previously reported dFdC derivatives
[33,37,39,41,58–65], including our own [25], but in many cases, the
derivatives were not more cytotoxic than dFdC alone against tumor
cells in culture [59,60,64]. Similarly, the chemical conjugates of
DHA and other cancer chemotherapeutic agents such as paclitaxel,
doxorubicin, and 10-hydroxycamptothecin were previously reported
as well, but the conjugates were not more cytotoxic than the original
agents in cell culture [12–14]. In fact, these conjugates were
considered prodrugs that need to be converted to active forms to be
effective [12,14]. Therefore, it was unexpected that DHA-dFdC
showed a potent broad-spectrum antitumor activity and was
significantly more cytotoxic than dFdC in pancreatic cancer cells
(e.g., in BxPC-3 cells, the IC50 value of DHA-dFdC was more than
100,000 fold smaller than that of the dFdC) and many of the NCI-60
DTP human tumor cell lines (Figure S2).DHA-dFdC induced tumor cells to undergo apoptosis (e.g.,
Panc-02 in Figure 3F), and it is expected that the dFdC formed
following the hydrolysis of DHA-dFdC contributed to the apoptosis.
However, the mechanism underlying the potent antitumor activity of
DHA-dFdC appears to be different from that of dFdC alone and may
not even be primarily attributed to dFdC’s activity in inhibiting
nucleic acid synthesis [66–68]. For example, although the conjuga-
tion of DHA to the 4-NH2 group on the dFdC is expected to prevent
its deanimation, the mere protection of the 4-NH2 is not sufficient to
increase the antitumor activity of dFdC, as the 4-(N)-stearoyl dFdC, a
conjugate of dFdC with stearate in the 4-NH2 position, was not
significantly more cytotoxic than dFdC against various dFdC-
sensitive cancer cell lines [23,31,69]. Therefore, it is unlikely that
the potent antitumor activity of the DHA-dFdC was simply due to
the protection of the vulnerable amine group on the dFdC. Instead, it
appears that the omega-3 PUFA nature of the docosahexaenoyl group
in the DHA-dFdC is critical for its strong antitumor activity. ARA is a
Figure 7. Antitumor activity of DHA-dFdC against Panc-1-luc
human pancreatic tumors implanted SC in nude male mice.
Tumor cells (5 × 106 cells/mouse) were injected (SC) in the right
flank of mice on day 0. On day 5, mice were randomized and
treated with DHA-dFdC (50 mg/kg) or molar equivalents of DHA,
dFdC, or DHA + dFdC. Control mice were injected with an
aqueous solution of Tween 80/ethanol in 5% of mannitol as a
vehicle control. All treatments were given by IP injection twice a
week. (A) Tumor growth curves. (B) Mouse body weights. Data are
mean ± SD (n = 5-6). (aP b .05, DHA-dFdC versus other groups;
n.s., not significant).
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more cytotoxic than dFdC in the cell lines tested (Figure 3H). It was
reported previously that epoxy derivatives of DHA, formed by the
action of cytochrome p450 epoxygenases, exhibited antiproliferative,
antiangiogenic, and antimetastatic activity [70]. It is expected that
DHA-dFdC may also undergo oxidation at the 4 to 5, 7 to 8, 10 to
11, 13 to 14, 16 to 17, or 19 to 20 sites on its docosahexaenoyl
moiety to form the epoxy derivatives, and the oxidized metabolites of
DHA-dFdC may have antitumor activity as well. The potent in vitro
cytotoxicity of the DHA-dFdC may also be related to the more
extensive and/or faster cellular uptake of the DHA-dFdC by tumor
cells in culture than the uptake of the dFdC alone (Figure 4) but may
not be entirely attributed to the increased cellular uptake. For
example, when Panc-02 cells were treated with DHA-dFdC or dFdC
at high concentrations (e.g., 10-100 μM), cytotoxicity was detected
after only 4 hours of coincubation with DHA-dFdC but not with
dFdC (Figure 3D). The dFdC, which inhibits nucleic acid synthesisand thus cell proliferation, showed significant activity only after
prolonged incubation (Figure 3C). Therefore, it is possible that
DHA-dFdC, at least at high concentrations, may cause tumor cell
death in a cell cycle–independent manner, and the cell death is
unlikely to be simply due to the DHA moiety in the DHA-dFdC
because DHA alone at the same concentrations did not show
significant cytotoxicity after 4 hours of coincubation (Figure 3D).
Taken together, it appears that the mechanisms underlying the
cytotoxicity of the DHA-dFdC and dFdC alone are not identical, but
more experiments need to be carried out to understand how
DHA-dFdC causes cytotoxicity to tumor cells.
Another unexpected finding is the relatively longer residence time
of DHA-dFdC in pancreas after IV injection into mice as compared
with dFdC (Figure 5C). Although a high concentration of
DHA-dFdC in the pancreas does not necessarily indicate that the
content of DHA-dFdC in mouse pancreatic tumor tissues was also
high, one can expect the longer residence time of DHA-dFdC in
pancreas to increase the exposure of pancreatic tumor cells to
DHA-dFdC. The high accumulation of DHA-dFdC in the pancreas
is likely related to the slow elimination of the DHA-dFdC from
pancreatic tissues (Figure 5D), but the exact reason behind the
relatively slow pancreatic elimination remains unknown. Fukui et al.
previously reported that when a diet supplemented with fish oil was
given to nude mice for 2 weeks (orally), a relatively high level of
eicosapentanoic acid (another omega-3 fatty acid) was detected in the
pancreas of the mice compared with control mice that received diet
supplemented with corn oil [71]. Significantly higher pancreatic
accumulation of DHA was also reported by Fukui and coworkers
when compared with control mice [71], but the difference in DHA
levels between fish oil–fed and corn oil–fed mice was much less
pronounced than that reported with eicosapentanoic acid (about
1.5-fold vs. 5-fold) [71]. Li et al. also reported the synthesis of a DHA
and dFdC conjugate, although data were not presented to
demonstrate that the DHA was conjugated to the 4-NH2 group of
dFdC [72]. Nonetheless, the authors showed that DHA seemed to
help target compounds conjugated to it into cells whose membrane is
rich in phosphatidylethanolamine [72].
The unexpected higher accumulation of DHA-dFdC in pancreas
(relative to dFdC), in addition to its strong cytotoxicity in several
pancreatic tumor cell lines, prompted the evaluation of its antitumor
activity against pancreatic tumors in mouse models, and data in
Figures 6 to 9 clearly showed that DHA-dFdC, at a dosing regimen
that did not cause any observed side effects, effectively inhibited
pancreatic tumor growth in mice with spontaneously developed
PDAC and with subcutaneous or orthotopic Panc-1-luc human
pancreatic tumor xenografts. Panc-1 tumor cells are known to be
resistant to dFdC [73], which explains why dFdC at the dosing
regimen used did not significantly inhibit Panc-1-luc tumor growth
(Figures 8–9). The potent cytotoxicity of DHA-dFdC against
pancreatic tumor cells and their longer residence time in pancreas
may partially explain its observed potent antitumor activity against
orthotopic Panc-1 tumors in nude mice and pancreatic tumors
spontaneously developed in the Kras ink4a+/− transgenic mice. In
addition, data from the NCI-60 human tumor cell line screening
clearly showed that DHA-dFdC has potent broad-spectrum activity
against many tumor cells. Thus, it is not unreasonable to expect it
to show potent antitumor activity against other tumors such as
renal cell carcinoma and leukemia. In fact, DHA-dFdC was
significantly more effective than the molar equivalent dose of dFdC
Figure 8. Antitumor activity of DHA-dFdC against orthotopic Panc-1-luc pancreatic tumors in nude male mice. Panc-1-luc cells (1 × 106
cells/mouse) were injected in mouse pancreas. Four weeks later, mice were randomized and treated with DHA-dFdC (50 mg/kg) or dFdC
(26.1 mg/kg) (IP injection twice a week). (A) IVIS images of tumors in the fifth week and eighth week after the tumor implantation. (B)
Tumor weights at the end of the study. (C) A digital photograph of tumors at the end of the study. (D) Mouse body weight change during
treatments. Data shown in B and D are means ± SD (n = 5-7).
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cells (Figure S3). In summary, data in the present study clearly
demonstrated that covalently conjugating two pharmacologically
active compounds together can generate a new compound with
unexpected pharmacokinetics and efficacy profiles.
Conclusion
A novel amide (DHA-dFdC) was synthesized by conjugating DHA,
an omega-3 PUFA, with dFdC, a nucleoside analogue. DHA-dFdCshowed potent and broad-spectrum antitumor activity in cell culture
and high distribution in mouse pancreas after IV injection.
Importantly, DHA-dFdC effectively inhibited tumor growth in
transgenic mice that spontaneously develop pancreatic tumor and in
nude mice with orthotopic pancreatic tumor.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2015.11.012.
Figure 9. (A) Representative histological images of tumors from nude mice that were treated with DHA-dFdC or dFdC after the tumor
tissues were stained with H&E, anti–Ki-67, or anti–cleaved lamin-A antibodies. The areas outlined in green (in the H&E staining images)
represent necrosis. (B) Percentage of Ki-67 positively stained cells. (C) Percent of cleaved lamin A positively stained cells. *P b .05 against
control, **P b .05 against dFdC.
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